In the latest market close, Pfizer (PFE) reached $29.08, with a -0.27% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.77%. Meanwhile, the Dow ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie has been reporting an earnings decline because its former lead drug, Humira, lost patent-protected market exclusivity ...

Goldman Sachs senior biotechnology analyst in global investment research Chris Shibutani joins Market Domination Hosts Julie ...

In a previous interview, Lee hinted that a period of market volatility is expected, as 2024 heads for a soft landing.

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

Activist investor Starboard has taken a $1 billion stake in Pfizer, according to a report, Super Micro stock surges, and ...

Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...

On top of this, Pfizer also faces key patent expirations of certain older products, and earlier estimated this will result in ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 7. David ...

Verizon's strength stems from its dominant U.S. wireless market position, controlling approximately 40% of the postpaid phone ...

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Monday. Shares of Pfizer Inc PFE rose during ...